

# Access conditions in public funds: advocating for the public interest

Viviana Galli

*European Alliance for Responsible R&D  
and Affordable Medicines*

# Why it matters

- ▶ Ensure **equitable access, availability and affordability** of medicines, vaccines and other health technologies
- ▶ Guarantee public return on public investment in terms of **societal benefit**
- ▶ Promote **transparency** and increase **trust** in institutions
- ▶ Strengthen **accountability** for the allocation of taxpayers money

# Obstacles

- ▶ Funders worried to add red tape and limit interest
- ▶ Lack of knowledge on how to translate policy and principles into legal contracts □ MAPGuide
- ▶ Limitation to global health, PRNDs and areas of limited profitability
- ▶ Lack of coordination and support for other initiatives, such as WHO's C-TAP

# Some positive steps forward by the EU

- ▶ Open science
- ▶ Extra efforts for COVID-19
- ▶ COVID-19 Research Manifesto
  - Publicly accessible results
  - Open access of publications and data
  - Non-exclusive royalty-free licenses
  - **BUT:** limited in time, voluntary and not legally binding



**MAXIMISING THE ACCESSIBILITY OF  
RESEARCH RESULTS IN THE FIGHT  
AGAINST COVID-19**

# Food for thought

- ▶ How to push public institutions and funders to include access conditions in their contracts?
- ▶ How to monitor and follow-up on the clauses if funds are limited to certain stages of development?
- ▶ How to evaluate the “best” clauses to ensure equitable access?
- ▶ How to expand beyond emergencies such as COVID-19 and turn those practices from exceptions to mainstream?



# Thank you

Viviana Galli

[viviana@medicinesalliance.eu](mailto:viviana@medicinesalliance.eu)

*European Alliance for Responsible R&D  
and Affordable Medicines*